Vorapaxar in the secondary prevention of atherothrombotic events.

By D. A. Morrow, E. Braunwald, Marc P. Bonaca, S. Ameriso, A. Dalby, M. Fish, K. Fox, L. Lipka, Xuan Liu, J. Nicolau and 8 more. New England Journal of Medicine, 2012

900 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Hematology

View Paper: https://www.semanticscholar.org/paper/c4fb89d1c07fee56cdb002698da45c1cf7bd1cbe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Epidemiology

In Hematology

G. Moneta

Citations in the corpus

[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, result): “While the post-MI population represents only a subset of those included in the CHARISMA study and the overall results of the trial did not show benefit of DAPT as compared to aspirin alone, it seems justifiable to give credit to this subanalysis based on the consistency of results within multiple re”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “In 26 449 patients who had a history of MI, ischaemic stroke or PAD, the primary composite endpoint—CV death, MI or stroke—was significantly reduced with vorapaxar in addition to standard antiplatelet therapy, but with increased risk of moderate or severe bleeding.(480) Vorapaxar cannot be recommend”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “In 26 449 patients who had a history of MI, ischaemic stroke or PAD, the primary composite endpoint—CV death, MI or stroke—was significantly reduced with vorapaxar in addition to standard antiplatelet therapy, but with increased risk of moderate or severe bleeding.(480) Vorapaxar cannot be recommend”
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (2016, background): “The use of ultrasound-accelerated catheter delivery of thrombolytic agents has been published in case series384 and retrospective analyses.385 However, the single RCT comparing this technique to standard catheter-based thrombolytic therapy failed to demonstrate a difference in outcomes, including bl”
The management of antithrombotic agents for patients undergoing GI endoscopy. (2016, background): “org and need for revascularization procedures in patients with a previous MI or peripheral artery disease when prescribed in conjunction with traditional dual antiplatelet therapy (DAPT).(50) However, this intensification of antiplatelet effect, via a novel pathway, is associated with an increased r”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “stroke—was significantly reduced with vorapaxar in addition to standard antiplatelet therapy, but with increased risk of moderate or severe bleeding [480].”
Global vascular guidelines on the management of chronic limb-threatening ischemia (2019, background): “Strategies are urgently required to improve availability and affordability of drugs so that vascular specialists can treat their patients to target.321 There have been concerns that drugs reducing heart rate and blood pressure will worsen ischemia in patients with PAD.”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “The only available PAR-1 inhibitor (vorapaxar) is contraindicated in patients with a history of stroke, TIA, or intracranial hemorrhage [390, 391].”